344 related articles for article (PubMed ID: 25200093)
41. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases.
Peña C; Pujol M; Ardanuy C; Ricart A; Pallares R; Liñares J; Ariza J; Gudiol F
Antimicrob Agents Chemother; 1998 Jan; 42(1):53-8. PubMed ID: 9449260
[TBL] [Abstract][Full Text] [Related]
42. Characteristics and outcomes of Klebsiella pneumoniae bacteraemia in Hong Kong.
Pau CK; Ma FF; Ip M; You JH
Infect Dis (Lond); 2015 May; 47(5):283-8. PubMed ID: 25697339
[TBL] [Abstract][Full Text] [Related]
43. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study.
Liu SW; Chang HJ; Chia JH; Kuo AJ; Wu TL; Lee MH
J Microbiol Immunol Infect; 2012 Apr; 45(2):113-9. PubMed ID: 22154994
[TBL] [Abstract][Full Text] [Related]
44. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.
Tumbarello M; Spanu T; Sanguinetti M; Citton R; Montuori E; Leone F; Fadda G; Cauda R
Antimicrob Agents Chemother; 2006 Feb; 50(2):498-504. PubMed ID: 16436702
[TBL] [Abstract][Full Text] [Related]
45. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome.
Nasa P; Juneja D; Singh O; Dang R; Singh A
Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253
[TBL] [Abstract][Full Text] [Related]
46. Clinical and microbiologic characteristics of adult patients with recurrent bacteraemia caused by extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee CH; Su LH; Chen FJ; Tang YF; Chien CC; Liu JW
Clin Microbiol Infect; 2015 Dec; 21(12):1105.e1-8. PubMed ID: 26271718
[TBL] [Abstract][Full Text] [Related]
47. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.
Paterson DL; Ko WC; Von Gottberg A; Mohapatra S; Casellas JM; Goossens H; Mulazimoglu L; Trenholme G; Klugman KP; Bonomo RA; Rice LB; Wagener MM; McCormack JG; Yu VL
Clin Infect Dis; 2004 Jul; 39(1):31-7. PubMed ID: 15206050
[TBL] [Abstract][Full Text] [Related]
48. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
[TBL] [Abstract][Full Text] [Related]
49. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.
Song W; Moland ES; Hanson ND; Lewis JS; Jorgensen JH; Thomson KS
J Clin Microbiol; 2005 Sep; 43(9):4891-4. PubMed ID: 16145169
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
Kang CI; Kim SH; Kim DM; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW
Infect Control Hosp Epidemiol; 2004 Oct; 25(10):860-7. PubMed ID: 15518030
[TBL] [Abstract][Full Text] [Related]
51. Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum β-lactamase-producing Klebsiella pneumoniae.
Saely S; Kaye KS; Fairfax MR; Chopra T; Pogue JM
Am J Infect Control; 2011 Jun; 39(5):390-395. PubMed ID: 21255875
[TBL] [Abstract][Full Text] [Related]
52. Risk factors and molecular epidemiology of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in Xiamen, China.
Deng J; Li YT; Shen X; Yu YW; Lin HL; Zhao QF; Yang TC; Li SL; Niu JJ
J Glob Antimicrob Resist; 2017 Dec; 11():23-27. PubMed ID: 28842361
[TBL] [Abstract][Full Text] [Related]
53. Emerging extended-spectrum β-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case-control-control study.
Boix-Palop L; Xercavins M; Badía C; Obradors M; Riera M; Freixas N; Pérez J; Rodríguez-Carballeira M; Garau J; Calbo E
Int J Antimicrob Agents; 2017 Aug; 50(2):197-202. PubMed ID: 28552471
[TBL] [Abstract][Full Text] [Related]
54. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections.
Viale P; Giannella M; Lewis R; Trecarichi EM; Petrosillo N; Tumbarello M
Expert Rev Anti Infect Ther; 2013 Oct; 11(10):1053-63. PubMed ID: 24073806
[TBL] [Abstract][Full Text] [Related]
55. Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia.
Ku NS; Kim YC; Kim MH; Song JE; Oh DH; Ahn JY; Kim SB; Kim HW; Jeong SJ; Han SH; Kim CO; Song YG; Kim JM; Choi JY
Arch Gerontol Geriatr; 2014; 58(1):105-9. PubMed ID: 23988261
[TBL] [Abstract][Full Text] [Related]
56. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Park SY; Kang CI; Joo EJ; Ha YE; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2012 Oct; 18(5):518-24. PubMed ID: 22742454
[TBL] [Abstract][Full Text] [Related]
58. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
59. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
60. The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study.
Behar PR; Teixeira PJ; Fachel JM; Kalil AC
J Hosp Infect; 2008 Feb; 68(2):123-9. PubMed ID: 18192077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
